Bayer AG’s consumer health sales stumbled again in the company's latest quarter as sales slumped for brands including Coppertone sunscreen and skin care products and the One A Day vitamin and supplement line.
Sales of the Claritin line slowed by a late start to the US allergy season and supply disruptions for Bayer Aspirin also held back Bayer's growth in the consumer health sector during its fiscal 2018 second quarter. Global sales, adjusted for foreign exchange and portfolio impacts, declined for the Claritin (loratadine) allergy brand 5.7% to 140bn ($162
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?